Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34733
Abstract: In this first‐in‐human phase 1b study (ClinicalTrials.gov identifier NCT02761694) of advanced solid tumors with PIK3CA/AKT/PTEN mutations, the authors investigated the safety and efficacy of the pan‐AKT inhibitor vevorisertib (MK‐4440; ARQ 751) as monotherapy or with… read more here.
Keywords: pan akt; pik3ca akt; solid tumors; phase study ... See more keywords
Population Pharmacokinetics of Z-Endoxifen in Patients with Advanced Solid Tumors.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2053
Abstract: The purpose of this study was to develop and validate a population pharmacokinetic model for Z-endoxifen in patients with advanced solid tumors and to identify clinical variables that influence pharmacokinetic parameters. Z-endoxifen-HCl was administered orally… read more here.
Keywords: advanced solid; endoxifen patients; patients advanced; solid tumors ... See more keywords
Population Pharmacokinetics of Monalizumab in Patients with Advanced Solid Tumors.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of clinical pharmacology"
DOI: 10.1002/jcph.2220
Abstract: Monalizumab is a novel, first-in-class humanized immunoglobulin G (IgG)-4 monoclonal antibody (mAb) immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. The objectives of this analysis were to develop a population pharmacokinetic (PK) model of… read more here.
Keywords: volume distribution; patients advanced; population pharmacokinetics; solid tumors ... See more keywords
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-02852-4
Abstract: Rationale exists for combining immune checkpoint inhibitors and PARP inhibitors (PARPi), and results of clinical trials in ovarian cancer are promising, but data in other cancers are limited. Efficacy and safety of PARPi/anti-PD-1 in advanced… read more here.
Keywords: parp inhibitors; solid tumors; advanced solid; efficacy safety ... See more keywords
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-017-3245-5
Abstract: PurposeLY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary objective of this phase I study was to determine a phase II dose in patients with advanced solid tumors. Secondary objectives… read more here.
Keywords: advanced solid; solid tumors; anti tgf; patients advanced ... See more keywords
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3661-1
Abstract: PurposeAfatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.MethodsAs part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), we determined the maximum tolerated dose… read more here.
Keywords: solid tumors; advanced solid; carboplatin carboplatin; carboplatin ... See more keywords
A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-018-3725-2
Abstract: PurposeBEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K pathway. This was an open-label, multicenter, dose-escalation, phase I study of single-agent BEZ235… read more here.
Keywords: solid tumors; advanced solid; bez235; study ... See more keywords
The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Chemotherapy and Pharmacology"
DOI: 10.1007/s00280-019-03880-9
Abstract: PurposeTo evaluate the effect of lapatinib on the QTc interval and ECG parameters in patients with advanced solid tumors.MethodsThis was a multicenter, placebo-controlled study in subjects with advanced solid tumors. Subjects were administered two doses… read more here.
Keywords: advanced solid; solid tumors; placebo controlled; study ... See more keywords
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial
Sign Up to like & getrecommendations! Published in 2018 at "Gastric Cancer"
DOI: 10.1007/s10120-018-0903-1
Abstract: BackgroundAvelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor JPN, a phase 1 trial of avelumab in Japanese patients with… read more here.
Keywords: trial; advanced solid; expansion; solid tumors ... See more keywords
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2020 at "Investigational New Drugs"
DOI: 10.1007/s10637-020-00936-z
Abstract: Purpose Combining small-molecule inhibitors of different targets was shown to be synergistic in preclinical studies. Testing this concept in clinical trials is, however, daunting due to challenges in toxicity management and efficacy assessment. This study… read more here.
Keywords: inhibitor; advanced solid; solid tumors; study ... See more keywords
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies
Sign Up to like & getrecommendations! Published in 2021 at "Investigational New Drugs"
DOI: 10.1007/s10637-021-01175-6
Abstract: Purpose. Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels of signal transduction may improve… read more here.
Keywords: combination; inhibitor; cediranib selumetinib; advanced solid ... See more keywords